Emergent Biosolutions Inc Dossier - Source-backed chat

Emergent Biosolutions Inc

EBSNYSE

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.91

Intrinsic Value $8.78median of 3 methodsbased on filings through 30 Jun 2026

Market Price $6.37Price as of 1 Oct 2026

UndervaluedIntrinsic value is 38% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $326.6M

Enterprise Value $768.7M

Shares Outstanding 51.7M diluted

Moat Rating None

Next Earnings Date28 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Emergent BioSolutions is executing a multi-year turnaround strategy under CEO Joe Papa, focusing on debt reduction, cost controls, and core franchises. While the company achieved profitability in 2025 and delivered a strong Q1 2026 earnings beat, management's full-year 2026 guidance represents a sharp reset. Revenue is projected to decline to $720M-$760M (down from $742.9M in 2025) with an expected return to a GAAP net loss of $10M-$30M. The company faces persistent headwinds, including competitive pressures on its key NARCAN naloxone franchise, lumpy and unpredictable government biodefense procurement, and high interest expenses on its debt. Despite trading at a deep valuation discount, these structural challenges and near-term margin compression justify a cautious Hold rating.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.00

Mean target$11.00

High · most bullish analyst$12.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Rapid market share erosion of the NARCAN franchise due to aggressive generic pricing and alternative OTC products. Government procurement delays or budget cuts lead to a failure to renew key biodefense contracts. Operating margins compress further, and the company's high leverage limits its strategic flexibility, leading to potential liquidity concerns.

Base CaseCentral scenario

The company successfully stabilizes its core biodefense contracts and maintains a stable market share in the opioid overdose reversal market despite generic competition. Cost-cutting measures continue to support adjusted EBITDA margins, and the company gradually reduces its debt load. However, top-line growth remains flat to slightly negative, and GAAP net income remains pressured by interest expenses.

Bull CaseUpside scenario

Emergent BioSolutions' turnaround is driven by strong demand for its Narcan and Kloxxado naloxone products, expanding international sales of medical countermeasures (accounting for 40-48% of MCM sales), and securing high-value government contracts (such as a $64.5M botulism antitoxin modification and a $52.7M smallpox/mpox vaccine contract). Additionally, the company has improved its financial flexibility through a $150M term loan refinancing and cost-reduction initiatives.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong leadership under turnaround specialist CEO Joe Papa, driving aggressive cost-saving initiatives and debt reduction.
Established, long-standing relationships with U.S. government agencies (BARDA, DoD) for critical biodefense stockpiling.
Refinanced debt structure that increases strategic flexibility and reduces near-term interest payment pressures.

Key Investment Risks

High concentration and competitive erosion of the NARCAN naloxone franchise due to generic and OTC alternatives.
Lumpy, unpredictable, and government-dependent revenue streams for medical countermeasures (MCM).
Significant debt load ($413.3M net debt as of Q1 2026) resulting in high interest expenses that eat into operating profits.

Thesis Invalidation Triggers

A drop in full-year 2026 revenue guidance below the $720 million floor.
Loss of a major government biodefense contract or failure to secure expected contract modifications.
Naloxone gross margins falling below 15% due to severe pricing pressure.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.